Justification of the possibility of using psychopharmacotherapy to overcome the negative impact of the Russian war on the population’s mental health
Abstract
The research purpose is to characterize Psychedelic- Assisted Therapy (PAT) and outline prospects for its implementation in Ukraine. Methodology and methods. Methods of theoretical analysis of scientific literature were used. Results. It was found that according to preliminary estimates, at least 23.5 million Ukrainian citizens are at risk of mental health deterioration: up to 20.0% – moderate and severe; about 70.0% – mild. It is indicated that one of the ways to overcome that kind of problem is to introduce psychotherapy augmented by certain psychoactive substances (MDMA, psilocybin, ketamine, etc.) in Ukraine. It is noted that the combined method has been designated as a breakthrough therapy in the USA since it is three times more effective than traditional psychotherapy methods and twice more effective than traditional drug treatment for PTSD (post-traumatic stress disorder) with shorter treatment duration and similar safety. It is emphasized that in the pre-war period, Ukraine, with the support of international partners, began work on creating a theoretical scientific basis and human resource development for further PAT implementation. It is noted that PAT implementation is now impossible in Ukraine due to the operation of outdated legislation that does not take into account the latest scientific achievement. In particular, it refers to the Resolution of the Cabinet of Ministers of Ukraine dated May 6, 2000, No. 770, which prohibits the use of psychotropic substances necessary for PAT, and the Order of the Ministry of Health of Ukraine dated April 15, 2008, No. 199, which does not consider the possibility of using such combined therapeutic modalities as PAT. Conclusions. It is justified that in view of the tremendous exacerbation of the issue of Ukrainians’ mental health due to the war unleashed by Russia, it is recommended emergently amending the Resolution of the Cabinet of Ministers of Ukraine dated May 6, 2000, No. 770 (to transfer MDMA, DMT, psilocybin and psilocin from List 2 of Table 1 to List 2 of Table 2 of the relevant resolution) and taking measures to ensure the availability of PAT for people in need, in particular, by implementing an expanded access program.
Downloads
References
American Psychological Association. (2017). Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD). Washington, DC APA, Guidel. Dev. Panel Treat. Posttraumatic Stress Disord. Adults, 139. Retrieved from: https://www.apa.org/ptsd-guideline
Attanayake, V., McKay, R., Joffres, M., Singh, S., Burkle Jr, F., & Mills, E. (2009). Prevalence of mental disorders among children exposed to war: a systematic review of 7.920 children. Medicine Conflict and Survival, 25(1), 4-19. https://doi.org/10.1080/13623690802568913
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1), 1-14. https://doi.org/10.1038/s41598-020-59282-y
Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7-19. https://doi. org/10.1016/j.neuropharm.2018.02.018
Bird, C. I., Modlin, N. L., & Rucker, J. J. (2021). Psilocybin and MDMA for the treatment of trauma-related psychopathology. International Review of Psychiatry, 33(3), 229-249. https://doi.org/10.1080/095 40261.2021.1919062
Bogic, M., Njoku, A., & Priebe, S. (2015). Long-term mental health of war-refugees: a systematic literature review. BMC international health and human rights, 15(1), 1-41. https://doi.org/10.1186/ s12914-015-0064-9
Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Progress in neuro-psychopharmacology and biological psychiatry, 84, 221-228. https://doi. org/10.1016/j.pnpbp.2018.03.003
Food and Drug Administration. (2017). Grant– Breakthrough Therapy Designation. Retrieved from: https://maps.org/wp-content/ uploads/2017/08/2017.08.15-IND063384Grant- BreakthroughTherapyDesignation1_Redacted.pdf
Gostin, L. O., & Rubenstein, L. S. (2022). Attacks on Health Care in the War in Ukraine: International Law and the Need for Accountability. JAMA, 327(16), 1541–1542. https://doi.org/10.1001/ jama.2022.6045
Grof, S. (2006). When the impossible happens: Adventures in non-ordinary realities. Sounds True. Haichin, M. (2022). Psychedelics Drug Development Tracker. Retrieved May 1, 2022, from: https://psilocybinalpha. com/data/psychedelic-drug-development- tracker
Howes, O. D., Thase, M. E., & Pillinger, T. (2022). Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry, 27, 58-72. Животовська, Л. В., Бойко, Д. І., Сокіл, А. А., Погорілко, О. В., & Волошин, В. А. (2019). Сучасні підходи до фармакотерапії посттравматичного стресового розладу. Вісник проблем біології і медицини, 2(2), 38-44.
Koek, R. J., Schwartz, H. N., Scully, S., Langevin, J.-P., Spangler, S., Korotinsky, A., … Leuchter, A. (2016). Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 70, 170–218. https://doi.org/10.1016/j.pnpbp.2016.01.01 Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Journal of psychoactive drugs, 29(2), 165-183. https://doi.org/10.1080/0 2791072.1997.10400185
Merz, J., Schwarzer, G., & Gerger, H. (2019). Comparative efficacy and acceptability of pharmacological, psychotherapeutic, and combination treatments in adults with posttraumatic stress disorder: a network meta-analysis. JAMA psychiatry, 76(9), 904-913. https://doi.org/10.1001/jamapsychiatry. 2019.0951
Мильштейн, Г. И., & Спивак, Л. И. (1971). Психотомиметики. Медицина. Ленингр. Отд-ние.
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033. https://doi.org/10.1038/s41591-021-01336-3
Murthy, R. S., & Lakshminarayana, R. (2006). Mental health consequences of war: a brief review of research findings. World psychiatry, 5(1), 25.
Thase, M., & Connolly, K. R. (2019). Ketamine and esketamine for treating unipolar depression in adults: administration, efficacy, and adverse effects. Retrieved from: https://www.uptodate.com/contents/ ketamine-and-esketamine-for-treating-unipolar- depression-in-adults-administration-efficacy- and-adverse-effects Young, F. L. (1986). Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of Administrative Law Judge. Submitted in the Matter of MDMA Scheduling, Docket No. 84-88, May 22.
Authors who publish with scientific journal agree to the following terms:
• All scientific papers may be freely copied and distributed on any medium and in any format, provided that the references to the initial data of the scientific work are indicated.
• Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed Creative Commons Attribution License .
• Authors are able to enter into separate, additional contractual arrangements for the non- exclusive distribution of the journal’s published version of the work (institutional repository, your website, monograph), with an acknowledgement of its initial publication in this journal.
